雄激素剥夺与放射治疗对前列腺癌MRI纤维束示踪的影响:能否在影像上评估治疗反应?
研究纳入22例PSA升高且活检证实前列腺癌的患者,在1.5T MRI联合直肠内线圈下比较接受雄激素剥夺和/或放射治疗组(n=11)与Gleason匹配的未治疗对照组(n=11)的弥散张量纤维束示踪定量参数,发现对照组肿瘤区与正常前列腺实质的纤维束密度和数量差异有统计学意义(p=0.0018),而治疗组无统计学显著差异(p=0.11),治疗后肿瘤与正常实质的纤维束数量差异似乎缩小。
要点
- 定量DTI纤维束示踪可作为前列腺癌治疗后的影像生物标志物。
- 对照组肿瘤区与正常实质的纤维束密度和数量差异有统计学意义(p=0.0018)。
- 治疗组肿瘤区与正常实质的纤维束密度和数量差异无统计学意义(p=0.11)。
核心结论
- 研究显示纤维束示踪可作为前列腺癌患者治疗后的生物标志物。
研究设计与样本
- 研究纳入22例PSA升高且活检证实前列腺癌的患者,均行1.5T MRI联合直肠内线圈检查;研究组11例接受雄激素剥夺和/或放射治疗,Gleason匹配的对照组11例未接受上述治疗;由弥散加权图像生成DTI三维纤维束图,在肿瘤区和健康前列腺实质绘制三维感兴趣区记录纤维束数量和纤维束密度。
诊断标准与关键数值
- 研究组肿瘤区纤维束密度2.3、纤维束数量116.6,正常实质纤维束密度3.3、纤维束数量170.2。
- 对照组肿瘤区纤维束密度1.6、纤维束数量252.5,正常实质纤维束密度2.7、纤维束数量346.3。
- 对照组肿瘤区与正常实质的纤维束密度和数量差异有统计学意义(p=0.0018)。
- 研究组肿瘤区与正常实质的纤维束密度和数量差异无统计学意义(p=0.11)。
临床应用与阅片要点
- 作者认为定量DTI纤维束示踪是定量评估前列腺癌雄激素剥夺和放射治疗后治疗反应的有前景的影像生物标志物。
- 研究显示治疗后肿瘤区与正常实质的纤维束数量差异似乎缩小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate quantitative changes in Diffusion Tensor Magnetic Resonance Tractography in prostate cancer following androgen deprivation and radiation therapy.
METHODS: 22 patients with elevated PSA and biopsy proven prostate carcinoma who underwent MRI of the prostate at 1.5 T with an endorectal coil were included. Group A) was the study group (n = 11), participants who underwent androgen deprivation and/or radiation therapy and group B) were Gleason-matched control group (n = 11) participants who did not undergo such therapy. Diffusion weighted images were used to generate three-dimensional (3D) map of fiber tracts from DTI. 3D regions of interest (ROI) were drawn over the tumor and healthy prostatic parenchyma in both groups to record tract number and tract density. Tumor region and normal parenchymal tract densities within each group were compared.
RESULTS: Mean tract density in the tumor region and normal parenchyma was 2.3 and 3.3 in study group (tract numbers: 116.6 and 170.2 respectively) and 1.6 and 2.7 in the control group respectively (tract numbers: 252.5 and 346.3 respectively). The difference between these values was statistically significant for the control group (p = 0.0018) but not for the study group (p = 0.11). The difference between the tract numbers of tumor and normal parenchyma appears to narrow following therapy.
CONCLUSION: The study demonstrated utility in using tractography as a biomarker in prostate cancer patients post treatment.
ADVANCES IN KNOWLEDGE: Quantitative DTI fiber tractography is a promising imaging biomarker to quantitatively assess treatment response in the setting of post-androgen deprivation and radiation therapy for prostate cancer.
引用
- Hedgire S, Kilcoyne A, Tonyushkin A, et al. Effect of androgen deprivation and radiation therapy on MRI fiber tractography in prostate cancer: can we assess treatment response on imaging? Br J Radiol. 2018. PMID: 30209952. doi:10.1259/bjr.20170170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。